Related references
Note: Only part of the references are listed.Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin
Brad Poore et al.
NEURO-ONCOLOGY (2019)
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Anna Hernandez-Prat et al.
MOLECULAR CANCER RESEARCH (2019)
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Fabiana Conciatori et al.
CANCERS (2018)
Trametinib for progressive pediatric low-grade gliomas
Maria Kondyli et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Kathleen N. Moore et al.
ESMO OPEN (2018)
The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity
Jeffrey A. Rubens et al.
NEURO-ONCOLOGY (2017)
Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
Payal Jain et al.
ONCOTARGET (2017)
Probing the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Pathway in Gliomas: A Phase 2 Study of Everolimus for Recurrent Adult Low-Grade Gliomas
Michael Wahl et al.
CANCER (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Victoria L. Bridgeman et al.
MOLECULAR CANCER THERAPEUTICS (2016)
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Aleksandra Olow et al.
CLINICAL CANCER RESEARCH (2016)
DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Allison R. Hanaford et al.
CLINICAL CANCER RESEARCH (2016)
ROCK inhibitor Y27632 promotes proliferation and diminishes apoptosis of marmoset induced pluripotent stem cells by suppressing expression and activity of caspase 3
Yuehong Wu et al.
THERIOGENOLOGY (2016)
The Chromatin-Modifying Protein HMGA2 Promotes Atypical Teratoid/Rhabdoid Cell Tumorigenicity
Harpreet Kaur et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2015)
Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target
Melanie F. Weingart et al.
ONCOTARGET (2015)
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Sarah J. Welsh et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth
Aparna Kaul et al.
NEURO-ONCOLOGY (2015)
FINAL RESULTS OF A PROSPECTIVE MULTI-INSTITUTIONAL PHASE II STUDY OF EVEROLIMUS (RAD001), AN MTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA. A POETIC CONSORTIUM TRIAL
Mark W. Kieran et al.
NEURO-ONCOLOGY (2014)
An introduction to the wound healing assay using live-cell microscopy
James E. N. Jonkman et al.
CELL ADHESION & MIGRATION (2014)
Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
Hemant K. Bid et al.
CLINICAL CANCER RESEARCH (2013)
New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model
Eric Raabe et al.
CLINICAL CANCER RESEARCH (2013)
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target
Marianne Huett-Cabezas et al.
NEURO-ONCOLOGY (2013)
Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas
Eugene I. Hwang et al.
PEDIATRIC BLOOD & CANCER (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
Craig Horbinski et al.
NEURO-ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma
Erika F. Rodriguez et al.
ACTA NEUROPATHOLOGICA (2011)
BRAF Activation Induces Transformation and Then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model
Eric H. Raabe et al.
CLINICAL CANCER RESEARCH (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Endothelial FAK is required for tumour angiogenesis
Bernardo Tavora et al.
EMBO MOLECULAR MEDICINE (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Initial Testing (Stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2010)
Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development
Dorine A. Bax et al.
PLOS ONE (2009)
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Stefan Pfister et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma
Eli E. Bar et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines
MS Bobola et al.
CLINICAL CANCER RESEARCH (2005)
Share Paper
